RET and breast carcinoma: The increasing use of NGS platforms has uncovered both classical and novel RET mutations in other cancers, including RET-C634R in breast carcinoma, RET-E511K in endometrial and Merkel-cell carcinomas, RET-M918T in a paraganglioma and atypical lung carcinoid and RET-V804M in colorectal carcinoma, meningioma, gastrointestinal stromal tumors (GIST) and hepatoma (9) (Figure 2).